Radioactive metaiodobenzylguanidine (131I-MIBG) is taken up specifically by neuroblastoma cells and appears to represent a new treatment modality in patients with advanced neuroblastoma. Taking into account the fact that all patients so far treated were heavily pretreated and resistant to chemotherapy, the results obtained appear encouraging. In order to explore further the potential role of this new drug in untreated patients, we treated with 131I-MIBG a child with stage III neuroblastoma at diagnosis. We observed the complete disappearance of a large abdominal tumor mass after a relatively low dosage of 131I-MIBG, with minimal hematologic toxicity. No further treatment was given and, at present, the patient is alive with no evidence of disease 18 months from diagnosis. This child represents, to our knowledge, the only case of neuroblastoma thus far treated at diagnosis and the excellent response obtained suggests the need for further investigations of this therapy in untreated patients.

Mastrangelo, R., Troncone, L., Lasorella, A., Riccardi, R., Montemaggi, P., Rufini, V., I-131 METAIODOBENZYLGUANIDINE IN THE TREATMENT OF NEUROBLASTOMA AT DIAGNOSIS, <<AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY>>, 1989; 11 (1): 28-31 [http://hdl.handle.net/10807/16313]

I-131 METAIODOBENZYLGUANIDINE IN THE TREATMENT OF NEUROBLASTOMA AT DIAGNOSIS

Troncone, Luigi;Riccardi, Riccardo;Rufini, Vittoria
1989

Abstract

Radioactive metaiodobenzylguanidine (131I-MIBG) is taken up specifically by neuroblastoma cells and appears to represent a new treatment modality in patients with advanced neuroblastoma. Taking into account the fact that all patients so far treated were heavily pretreated and resistant to chemotherapy, the results obtained appear encouraging. In order to explore further the potential role of this new drug in untreated patients, we treated with 131I-MIBG a child with stage III neuroblastoma at diagnosis. We observed the complete disappearance of a large abdominal tumor mass after a relatively low dosage of 131I-MIBG, with minimal hematologic toxicity. No further treatment was given and, at present, the patient is alive with no evidence of disease 18 months from diagnosis. This child represents, to our knowledge, the only case of neuroblastoma thus far treated at diagnosis and the excellent response obtained suggests the need for further investigations of this therapy in untreated patients.
Inglese
Mastrangelo, R., Troncone, L., Lasorella, A., Riccardi, R., Montemaggi, P., Rufini, V., I-131 METAIODOBENZYLGUANIDINE IN THE TREATMENT OF NEUROBLASTOMA AT DIAGNOSIS, <<AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY>>, 1989; 11 (1): 28-31 [http://hdl.handle.net/10807/16313]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/16313
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 16
social impact